Akari Therapeutics, Plc fell 12.6% on Thursday, November 12, 2026, on 14,500 shares. Headlines around the move:
Akari Therapeutics, Plc (AKTX:NASDAQ) closed at $6.80 on November 13, 2026, down 1.45% on the day. The stock trades 76.8% below its 52-week high of $29.32 and 125.5% above its 52-week low of $3.02. Over the past year, it lost 67.9%. Akari Therapeutics, Plc is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, AKTX closed higher on 109 days (43%). Its best day was May 22, 2026 (+255.45%) and its worst was May 12, 2026 (-40.58%). The stock moved 10% or more in a single session 39 times. It opened at least 5% above the previous day's high 2 times.
As of September 18, 2015, Celsus Therapeutics Plc was acquired by Akari Therapeutics, Plc, in a reverse merger transaction. Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-ste...
Find more stocks like AKTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.